KIORA PHARMACEUTICALS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $16.0M | $0 | — | $0 |
| Research and development | $10.8M | $7.8M | $4.0M | $3.4M | $5.4M |
| Operating expenses | $12.8M | $11.5M | $12.6M | $12.3M | $14.2M |
| Operating income | -$12.8M | $4.5M | -$12.6M | -$12.3M | -$14.2M |
| Interest expense | $19,960 | $21,446 | $11,132 | $8,599 | $6,851 |
| Pretax income | -$12.1M | $5.7M | -$12.4M | -$13.7M | -$14.0M |
| Income tax expense | -$1.3M | $2.1M | $90,319 | -$113,010 | -$192,603 |
| Net income | -$10.8M | $3.6M | -$12.5M | -$13.6M | -$13.8M |
| Balance Sheet | |||||
| Cash and equivalents | $8.7M | $3.8M | $2.5M | $6.0M | $7.9M |
| Current assets | $21.7M | $29.7M | $4.7M | $7.7M | $9.0M |
| Total assets | $24.3M | $36.5M | $13.7M | $18.7M | $20.1M |
| Current liabilities | $3.6M | $6.0M | $1.6M | $3.3M | $1.6M |
| Total liabilities | $8.1M | $10.7M | $7.6M | $7.3M | $5.6M |
| Stockholders' equity | $16.1M | $25.8M | $6.1M | $11.4M | $14.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$10.0M | $8.6M | -$9.6M | -$10.4M | -$10.7M |
| Depreciation and amortization | $24,801 | $19,205 | $51,798 | $41,609 | $45,296 |
| Stock-based compensation | $900,236 | $656,593 | $754,944 | $462,450 | $842,475 |
| Capital expenditure | $110,789 | $6,256 | $0 | $0 | $63,865 |
| Free cash flow | -$10.1M | $8.6M | -$9.6M | -$10.4M | -$10.7M |
| Impairments | $0 | $104,167 | $0 | $0 | $4.0M |
Shares outstanding 4.4M · Free float 33.6%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.